Announcement
Cyrano Therapeutics Launches Clinical Study of CYR-064 for Smell Loss (Hyposmia) in Parkinson's Disease Patients.
Cyrano Therapeutics
PR-01-25-NI-32Feb 04, 2025
Announcement
AbbVie Announces Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
AbbVie
PR-12-24-NI-134Dec 11, 2024
Neurodegenerative Disease Clinical Trials
Preparing for Growth in Neurodegenerative Treatment Opportunities: How Clinical Teams can Best Position Study Design and Strategy to Reach Study Participants
John Hamlet; Christine Martino, MPM; Sabine Krofczik-Wilhelm, Ph.D.; Alberto Lledó, M.D., Ph.D.
PPD clinical research business of Thermo Fisher Scientific
PAO-09-022-CL-09Sep 27, 2022
Plant-Inspired Drug Discovery
Unlocking the Therapeutic Potential of Plant-Inspired Minimum Essential Mixtures
Andrea Small-Howard, Ph.D.
Gb Sciences, Inc.
PAO-08-022-CL-01Sep 06, 2022
Parkinson's Disease Research
Gb Sciences to Begin Dosage Study for Its Novel Parkinson's Disease Formulations at the University of Lethbridge
Gb Sciences, Inc.
PR-M04-22-08Apr 12, 2022
Neurodegenerative Diseases
Pioneering Nanocatalysis to Revolutionize Treatments for Neurodegenerative Diseases
Rob Etherington
PAO-01-22-CL-06Mar 12, 2022
Parkinsons's Disease
Novel Computational Approaches to Parkinson's Disease Drug Development
Eric Richman
PTV-08-21-CL-002Aug 18, 2021
Brain Organoids
Leveraging Organoids to Address Neurodegenerative Diseases
OrganoTherapeutics
PAO-04-22-R221-66-400Apr 29, 2021
Stem Cells
Changing the Paradigm of Stem Cell Technology
Sandy Solmon
Celavie Biosciences
PAP-Q4-20-CL-008Dec 09, 2020
Drug Repositioning
A Therapeutic Strategy for Neurological Disorders
Franck Mouthon; Mathieu Charvériat, Ph.D.
Theranexus
PAP-Q2-20-CL-016Jul 01, 2020
Cell and Gene Therapy
One-time Treatment Generates New Neurons, Eliminates Parkinson's Disease in Mice
University of California San Diego
PR-M06-20-NI-036Jun 30, 2020
FDA Approval
FDA Approves New Add-on Drug to Treat Off Episodes in Adults with Parkinson’s disease
U.S. Food & Drug Administration
PR-M08-19-NI-090Aug 30, 2019
Next-Generation Therapy
Smart Brain Stimulators: Next-Gen Parkinson’s Disease Therapy
University of Houston
PR-M07-19-NI-077Jul 30, 2019
Collaboration
New Collaboration Targets Parkinson’s Disease
Pharma's Almanac
PAO-M03-19-NI-005Mar 05, 2019
Phase 3 Study
Britannia Pharmaceuticals Ltd: Phase 3 TOLEDO Study Shows Apomorphine Infusion Provides Effective Relief of Persistent Motor Fluctuations in Parkinson's Disease
Britannia Pharmaceuticals
PR-M08-18-NI-043Aug 13, 2018